Proteon Therapeutics, Inc. (PRTO) EPS Estimated At $-0.29

October 11, 2018 - By Peter Erickson

Proteon Therapeutics, Inc. (NASDAQ:PRTO) LogoInvestors sentiment decreased to 0.86 in 2018 Q2. Its down 0.02, from 0.88 in 2018Q1. It worsened, as 6 investors sold Proteon Therapeutics, Inc. shares while 1 reduced holdings. 2 funds opened positions while 4 raised stakes. 7.28 million shares or 0.08% more from 7.27 million shares in 2018Q1 were reported.
Texas-based Dimensional Fund Advisors Lp has invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Northern Tru Corporation has 18,373 shares for 0% of their portfolio. Vanguard accumulated 143,550 shares. Moreover, Blackrock Inc has 0% invested in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Boothbay Fund Mgmt Limited Company has invested 0.02% of its portfolio in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Mpm Asset Mngmt holds 983,381 shares or 0.93% of its portfolio. Acadian Asset Limited Liability Com stated it has 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Deutsche Fincl Bank Ag reported 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Ra Cap Mngmt Ltd Liability Com, a Massachusetts-based fund reported 1.34 million shares. Deer Vii & Company has invested 0.92% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Panagora Asset has invested 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Abingworth Llp has 2.02 million shares for 2.77% of their portfolio. Renaissance Technology Limited stated it has 0% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Baker Bros Advsr L P stated it has 0.01% in Proteon Therapeutics, Inc. (NASDAQ:PRTO). Finance Counselors Inc, Missouri-based fund reported 50,000 shares.

Analysts expect Proteon Therapeutics, Inc. (NASDAQ:PRTO) to report $-0.29 EPS on November, 6.They anticipate $0.79 EPS change or 73.15 % from last quarter’s $-1.08 EPS. After having $-0.28 EPS previously, Proteon Therapeutics, Inc.’s analysts see 3.57 % EPS growth. The stock decreased 6.55% or $0.11 during the last trading session, reaching $1.57. About 40,397 shares traded. Proteon Therapeutics, Inc. (NASDAQ:PRTO) has risen 59.26% since October 11, 2017 and is uptrending. It has outperformed by 43.64% the S&P500.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The company has market cap of $27.83 million. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. It currently has negative earnings.

Another recent and important Proteon Therapeutics, Inc. (NASDAQ:PRTO) news was published by which published an article titled: “The Daily Biotech Pulse: Affimed’s Cancer Drug Placed On Clinical Hold, Celgene’s Positive Scalp Psoriasis Trial” on October 09, 2018.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.